TTM
$4.03B
YoY change
+5.1%
5Y CAGR
+8.7%
Peak year (2025)
$4.07B
Cumulative EBITDA
$35.02B
EBITDA history chart for Zoetis (ZTS) from 2009 to 2025
Latest: $4.07B
EBITDA growth chart for Zoetis (ZTS) from 2009 to 2025
Latest: +5.1%
EBITDA history table for Zoetis (ZTS) from 2009 to 2025
| 2025 | $4.07B | +5.1% | +$197.00M | ||
| 2024 | $3.87B | +5.1% | +$187.00M | ||
| 2023 | $3.69B | +9.7% | +$327.00M | ||
| 2022 | $3.36B | +5.9% | +$186.00M | ||
| 2021 | $3.17B | +18.1% | +$486.00M | ||
| 2020 | $2.69B | +9.4% | +$231.00M | ||
| 2019 | $2.46B | +11.1% | +$245.00M | ||
| 2018 | $2.21B | +13.8% | +$268.00M | ||
| 2017 | $1.94B | +18.8% | +$308.00M | ||
| 2016 | $1.63B | +88.2% | +$766.00M | ||
| 2015 | $868.00M | -23.9% | −$273.00M | ||
| 2014 | $1.14B | +13.0% | +$131.00M | ||
| 2013 | $1.01B | +7.3% | +$69.00M | ||
| 2012 | $941.00M | +48.2% | +$306.00M | ||
| 2011 | $635.00M | +58.8% | +$235.00M | ||
| 2010 | $400.00M | +19900.0% | +$398.00M | ||
| 2009 | $2.00M | — | — |
- 2025$4.07B+5.1%
- 2024$3.87B+5.1%
- 2023$3.69B+9.7%
- 2022$3.36B+5.9%
- 2021$3.17B+18.1%
- 2020$2.69B+9.4%
- 2019$2.46B+11.1%
- 2018$2.21B+13.8%
- 2017$1.94B+18.8%
- 2016$1.63B+88.2%
- 2015$868.00M-23.9%
- 2014$1.14B+13.0%
- 2013$1.01B+7.3%
- 2012$941.00M+48.2%
- 2011$635.00M+58.8%
- 2010$400.00M+19900.0%
- 2009$2.00M—
EBITDA values are taken from Zoetis's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Zoetis (ZTS)
According to Zoetis's latest reported financial statements, the company's current EBITDA (TTM) is $4.03B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Zoetis (ZTS) most recent annual EBITDA stands at $4.07B (2025) – grew 5.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Zoetis EBITDA compounded at +8.7% per year, sustaining 10 straight years of year-over-year growth.
Across the available history, EBITDA reached its high of $4.07B in 2025 and its low of $2.00M in 2009.
Zoetis EBITDA by Year
Zoetis EBITDA 2025: $4.07B
Zoetis EBITDA in 2025 was $4.07B, grew 5.1% from 2024. This figure represents the highest annual value in the available history.
Zoetis EBITDA 2024: $3.87B
2024's EBITDA for Zoetis came in at $3.87B, grew 5.1% from 2023.
Zoetis EBITDA 2023: $3.69B
Zoetis posted EBITDA of $3.69B in 2023, grew 9.7% from 2022.
Zoetis EBITDA 2022: $3.36B
In 2022, Zoetis reported EBITDA of $3.36B, grew 5.9% from 2021.
Zoetis EBITDA 2021: $3.17B
Zoetis EBITDA in 2021 was $3.17B.
See more financial history for Zoetis (ZTS).
Sector peers by EBITDA
Healthcare peers of Zoetis (ZTS), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Zoetis (ZTS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation